Despite significantadvances in therapy over the last decade CLL remains incurable. Current front-line therapy often consists of chemoimmunotherapy-based regimens,

most commonly the fludarabine, cyclophosphamide plus rituximab combination, but rates of relapse and refractory disease are high among these patients. Several key signaling pathways are now known to mediate the survival and proliferation of CLL cells 并且 in vivo, the most notable of which are the pathways mediated by the B-cell receptor(BCR) and cytokine receptors. A better understanding of the pathogenesis of the disease, the underlying biology of the CLL-cell and the roles of the tumour microenvironment has provided the rationale

for trials of a range of novel, more targeted therapeutic agents. In particular, clinical trials of ibrutinib and idelalisib, which target the Brutons tyrosine kinase and the delta isoform of phosphoinositol-3 kinase components of the BCR signaling pathway respectively, have shown extremely promising results. Here we review the current literature on the key signaling pathways and interactions of CLL cells that mediate the survival and proliferation of the leukemic 哪里 cells. For each we describe the results of the recent clinical trials and in vitro studies of novel therapeutic agents.
蛋白激酶B(AKT),在细胞存活、代谢、迁移和侵袭等信号通路中起着重要的调控作用。细胞信号转导抑制因子3(SOCS3)主要参与酪氨酸蛋白激酶(JAK)/信号传导子和转录激活子3(STAT3)传导途径的负反馈调节,可能参与AKT的磷酸化,进而调控肿瘤的发生。根据SOCS3蛋白的生物学特性和AKT信号通路的激活途径,综述了SOCS3在AKT信号通路中的调控作用,以期针对SOCS3靶向AKT信号通路进行抗肿瘤研究,为肿瘤的治疗提供一种新的思路。
目的:探讨蛋白激酶B(protein

CAL-101订单 kinase B,Akt)抑制剂MK-2206对胃癌细胞SGC-7901DNA损伤的影响。方法:不同浓度的MK-2206作用于SGC-7901细胞后,免疫荧光检测细胞内DNA损伤标记分子磷酸化组蛋白H2AX(γ-H2AX)焦点的生成,Western blot检测DNA损伤相关蛋白的表达水平,同时观察MK-2206对自噬标志蛋白LC3-II表达量的影响,用以确定MK-2206是否促进细胞发生自噬。结果:MK-2206能够诱导SGC-7901细胞发生DNA损伤,促进细胞内γ-H2AX焦点生成,并且激活DNA损伤相关蛋白的表达;MK-2206作用细胞后,LC3-II的生成增加;抑制细胞的自噬显著增强了MK-2206诱导的H2AX磷酸化水平。结论:Akt抑制剂MK-2206能够诱导细胞发生DNA损伤和自噬,抑制自噬促进了MK-2206诱导的DNA损伤。
目的探讨PI3K-AKT信号通路靶向抑制剂AKTiⅣ对慢性粒细胞白血病(CML)急变期细胞K562的影响及其对Wnt/β-catenin信号通路的调控作用。方法取处于对数生长期的K562细胞,分别加入0、2.5、5、10μmol/L的AKTiⅣ进行处理,采用MTT法检测其对细胞增殖的影响,甲基纤维素克隆形成实验检测细胞的克隆形成能力,Western blotting检测K562细胞中p AKT(Thr308)、p GSK-3β(Ser9)蛋白表达情况,荧光定量PCR和Western blotting检测β-catenin及其下游靶基因c-myc、cyclin D1 m RNA和蛋白表达情况。结果 AKTiⅣ作用6、10、16h后,K562细胞的增殖能力以及克隆形成能力明显受抑,且作用10h时抑制效果最好。2.